This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ammanamanchi, S. Articles by Brattain, M. G. Search for Related Content PubMed PubMed Citation Articles by Ammanamanchi, S. Articles by Brattain, M. G.

Endogenous Control of Cell Cycle Progression by Autocrine Transforming Growth Factor ß in Breast Cancer Cells

¹ Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York; ² Department of Pharmacology, Medical College of Ohio, Toledo, Ohio; and ³ Department of Surgery, The University of Texas Medical Branch, Galveston, Texas

Tumor progression due to loss of autocrine negative transforming growth factor-ß (TGF-ß) activity was reported in various cancers of epithelial origin. Estrogen receptor expressing (ER⁺) breast cancer cells are refractory to TGF-ß effects and exhibit malignant behavior due to loss or inadequate expression of TGF-ß receptor type II (RII). The exogenous TGF-ß effects on the modulation of cell cycle machinery were analyzed previously. However, very little is known regarding the endogenous control of cell cycle progression by autocrine TGF-ß. In this study, we have used a tetracycline regulatable RII cDNA expression vector to demonstrate that RII replacement reconstitutes autocrine negative TGF-ß activity in ER⁺ breast cancer cells as evidenced by the delayed entry into S phase by the RII transfectants. Reversal of the delayed entry into S phase by the RII transfectants in the presence of tetracycline in addition to the decreased steady state transcription from a promoter containing the TGF-ß responsive element (p3TP-Lux) by TGF-ß neutralizing antibody treatment of the RII transfected cells confirmed that autocrine-negative TGF-ß activity was induced in the transfectants. Histone H1 kinase assays indicated that the delayed entry of RII transfectants into phase was associated with markedly reduced cyclin-dependent kinase (CDK)2 kinase activity. This reduction in kinase activity was due to the induction of CDK inhibitors p21/waf1/cip1 and p27/kip, and their association with CDK2. Tetracycline treatment of RII transfectants led to the suppression of p21/waf1/cip1and p27/kip expression, thus, directly demonstrating induction of CDK inhibitors by autocrine TGF-ß leading to growth control of ER⁺ breast cancer cells.

This article has been cited by other articles:

				E. Esplugues, J. Vega-Ramos, D. Cartoixa, B. N. Vazquez, I. Salaet, P. Engel, and P. Lauzurica Induction of tumor NK-cell immunity by anti-CD69 antibody therapy Blood, June 1, 2005; 105(11): 4399 - 4406. [Abstract] [Full Text] [PDF]